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IMPORTANCE Little is known about whether the duration of adjuvant imatinib influences the
prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and
platelet-derived growth factor receptor α (PDGFRA) mutations.
OBJECTIVE To investigate the effect of KIT and PDGFRAmutations on recurrence-free survival
(RFS) in patients with gastrointestinal stromal tumors (GISTs) treated with surgery and
adjuvant imatinib.
DESIGN, SETTING, AND PARTICIPANTS This exploratory study is based on the Scandinavian
Sarcoma Group VIII/Arbeitsgemeinschaft Internistische Onkologie (SSGXVIII/AIO) multicenter
clinical trial. Between February 4, 2004, and September 29, 2008, 400 patients who had
undergone surgery for GISTs with a high risk of recurrence were randomized to receive
adjuvant imatinib for 1 or 3 years. Of the 397 patients who provided consent, 341 (85.9%) had
centrally confirmed, localized GISTs with mutation analysis for KIT and PDGFRA performed
centrally using conventional sequencing. During a median follow-up of 88months
(completed December 31, 2013), 142 patients had GIST recurrence. Data of the evaluable
population were analyzed February 4, 2004, through December 31, 2013.
MAIN OUTCOMES ANDMEASURES Themain outcomewas RFS. Mutations were grouped by
the gene and exon. KIT exon 11 mutations were further grouped as deletion or
insertion-deletionmutations, substitutionmutations, insertion or duplicationmutations, and
mutations that involved codons 557 and/or 558.
RESULTS Of the 341 patients (175men and 166women;median age at study entry, 62 years) in
the 1-year group and 60 years in the 3-year group), 274 (80.4%) hadGISTswith a KITmutation,
43 (12.6%) hadGISTs that harbored a PDGFRAmutation, and 24 (7.0%) hadGISTs that were
wild type for these genes. PDGFRAmutations and KIT exon 11 insertion or duplicationmutations
were associatedwith favorable RFS, whereas KIT exon 9mutationswere associatedwith
unfavorable outcome. Patients with KIT exon 11 deletion or insertion-deletionmutation had
better RFSwhen allocated to the 3-year group comparedwith the 1-year group (5-year RFS,
71.0%vs 41.3%; P < .001), whereas no significant benefit from the 3-year treatmentwas found
in the othermutational subgroups examined. KIT exon 11 deletionmutations, deletions that
involved codons 557 and/or 558, and deletions that led to pTrp557_Lys558del were associated
with poor RFS in the 1-year group but not in the 3-year group. Similarly, in the subset with KIT
exon 11 deletionmutations, higher-than-the-medianmitotic countswere associatedwith
unfavorable RFS in the 1-year group but not in the 3-year group.
CONCLUSIONS AND RELEVANCE Patients with KIT exon 11 deletionmutations benefit most
from the longer duration of adjuvant imatinib. The duration of adjuvant imatinib modifies the
risk of GIST recurrence associated with some KITmutations, including deletions that affect
exon 11 codons 557 and/or 558.
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G astrointestinal stromal tumor (GIST) is a common typeof sarcoma.1 Most GISTs are local when detected andare treated with surgery. Their malignancy potential
varies, with themost important factors associatedwith prog-
nosis after surgery being tumor mitotic rate and size, site in
the gastrointestinal tract, and presence of tumor rupture.2
Treatment with at least 3 years of imatinib is frequently
recommended for high-risk patients with GISTs.3,4 This rec-
ommendation is based on the randomized Scandinavian Sar-
coma Group (SSG) XVIII/Arbeitsgemeinschaft Internistische
Onkologie (AIO) trial that compared 3 years to 1 year of adju-
vant imatinib. The 3-year treatment improved recurrence-
free survival (RFS) and overall survival (OS).5 The American
College of Surgeons Oncology Group Z9001 trial that com-
pared 1 year of adjuvant imatinib with placebo and the Euro-
pean Organisation for Research and Treatment of Cancer
trial that compared 2 years of adjuvant imatinib to observa-
tion (each trial performed in part in a lower-risk patient
population) found adjuvant imatinib to improve RFS but not
OS.6-8 The reasons why the 3-year adjuvant imatinib treat-
ment resulted in an OS benefit whereas the shorter treat-
ments did not have remained speculative.
Activating mutations in KIT proto-oncogene receptor
tyrosine kinase (KIT) (encodes KIT protein) (OMIM 164920)
and less frequently in platelet-derived growth factor recep-
tor α (PDGFRA) (encodes platelet-derived growth factor
receptor α) (OMIM 173490) are considered the major
molecular drivers of most GISTs.9 The resulting aberrant
receptor tyrosine kinases are excellent targets for therapy
with tyrosine kinase inhibitors.10 Most KIT mutations are
deletion mutations in exon 11, and these deletions fre-
quently span the critical codons 557 and/or 558. KIT exon 11
mutations that involve codons 557 and/or 558 are associated
with poor prognosis in patient populations treated with
surgery.11-14 Some other KIT mutations, such as exon 11
insertion and duplication mutations and PDGFRA muta-
tions, are generally associated with favorable survival.13-15
However, the prognosis associated with single KIT or
PDGFRA mutations may vary greatly, depending on the
tumor mitotic rate, suggesting that further genetic aberra-
tions besides KIT and PDGFRA mutations contribute to the
clinical behavior of GIST.15
Mutation analysis of KIT and PDGFRA and possibly also
of other genes, such as B-Raf proto-oncogene, serine/
threonine kinase (BRAF) (OMIM 164757) and succinate dehy-
drogenase (SDH)A (OMIM600857),B (OMIM185470),C (OMIM
602413), and D (OMIM602690), is recommended also for es-
timation of GIST drug responsiveness. In particular, PDGFRA
exon 18mutationD842Vconfers imatinib resistance,whereas
mostKITexon 11deletionmutations arehighly sensitive.16 Pa-
tientswithadvancedGISTwithKITexon9mutation likelyben-
efit from a dose of imatinib that is higher than the standard
400mg.17
Little is known about whether the duration of adjuvant
imatinib influences the prognostic significance of KIT and
PDGFRA mutations. We studied this in the patient popula-
tion of the SSGXVIII/AIO trial that compared 2 durations of
adjuvant imatinib.
Methods
Participants
The SSGXVIII/AIO is an open-label, randomized,multicenter,
phase 3 trial inwhich theparticipantswere randomized for in-
tention to treat in a 1:1 ratio to receive 400 mg/d of adjuvant
imatinib orally for 1 or 3 years.5,18 The study, a protocol-based
prespecified analysis, was approved by the Operative Ethics
Committeeof theHelsinkiUniversityCentralHospital andcon-
ductedaccording to theGoodClinical Practice guidelines. The
participants providedwritten informed consent before study
entry. All data were deidentified.
Patients 18 years or older with Eastern Cooperative On-
cology Group performance status of 2 or less and GISTs com-
pletely excised macroscopically at open surgery were eli-
gible. Patientswithmetastatic, inoperable, or recurrentGISTs
and those with prior neoadjuvant imatinib therapy were ex-
cluded. Patients who were rendered free from all detectable
GISTmetastaseswith surgerywere allowed to participate un-
tilOctober 2006,when the studyprotocol18was amendedand
such patients were excluded.
The diagnosis of GISTs was made based on histologic as-
sessment and the expression of KIT on immunohistochemi-
cal analysis. The estimated risk of recurrencewas required to
behighaccording to themodifiedNational InstitutesofHealth
consensus criteria. High risk was defined as tumor diameter
greater than 10.0 cm, more than 10 mitoses per 50 high-
power fields (HPFs), diameter greater than 5.0 cm and mi-
totic count higher than 5, or presence of tumor rupture.5
Between February 4, 2004, and September 29, 2008, a
total of 400patientswere accrued from24 study sites.5 Three
patients who had been randomized without signing in-
formed consent forms were excluded from the analyses, and
we also excluded 15 patients who did not have GISTs at cen-
tral pathology review of the tumor tissue specimens, 24 pa-
tients with GIST metastases resected at surgery, and 17 pa-
tientswhodidnothavemutation analysis ofKIT andPDGFRA
performed centrally (Figure 1). Themedian follow-up timeaf-
ter the date of randomization of the 341 patients in the final
Key Points
Question Does the duration of adjuvant imatinib treatment (1
year or 3 years) influence the prognostic significance of KIT
proto-oncogene receptor tyrosine kinase (KIT) and
platelet-derived growth factor receptor α genotypes in the
treatment of patients with gastrointestinal stromal tumors?
Findings In this exploratory analysis of a randomized clinical trial
of 400 patients, 149 with a deletion in KIT exon 11 benefitted from
the 3-year duration, whereas patients with other genotypes had
little or no benefit. KIT exon 11 deletions were prognostic in the
1-year group but not in the 3-year group.
Meaning The duration of adjuvant imatinib treatment influences
the risk of gastrointestinal stromal tumor recurrence associated
with KIT deletionmutations, andmutation analysis aids in patient
selection for adjuvant imatinib.
KIT and PDGFRAMutations in Patients With Gastrointestinal Stromal Tumor Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology May 2017 Volume 3, Number 5 603
Downloaded From: http://oncology.jamanetwork.com/pdfaccess.ashx?url=/data/journals/oncology/936232/ by a HELSINKI UNIVERSITY LIBRARY User  on 06/15/2017
Copyright 2017 American Medical Association. All rights reserved.
study cohort was 88 months (range, 0.1-114 months). All pa-
tients were available for follow-up.
Procedures
Randomization was performed centrally.5 Staging was per-
formed before starting adjuvant imatinib with contrast-
enhanced computed tomography or magnetic resonance
imagingof theabdomenand thepelvis andwith computed to-
mography or radiography of the chest. Computed tomogra-
phy ormagnetic resonance imaging of the abdomenwas per-
formed at 6-month intervals until month 84 of the study and
then annually. Physical examination, blood cell counts, and
blood biochemical analyses were assessed periodically.5
Central Histopathologic Review
Local pathologistsmade thehistologicdiagnosis ofGISTs, and
GIST risk stratification was based on this assessment. Tumor
histologic findings were reviewed centrally during the study
by 1 of 2 pathologists with special interest in sarcoma pathol-
ogy. At central pathology review, 15 patients were found not
to have GISTs. The central pathologists also counted tumor
mitoses from 50 HPFs (the total HPF areas were 11.24 and
12.50 mm2).
Mutation Analysis
Mutation analysis of KIT and PDGFRA was not required for
study entry. KIT exons 9, 11, 13, and 17 and PDGFRA exons 12
and 18 were sequenced centrally during the study using con-
ventional sequencing.19,20
We focused on KIT exon 11 deletion mutations because
these are themost commonKIT aberrations inGISTs.Weclas-
sified thesemutations in 4 differentways: (1) presence of any
deletionor insertion-deletion (indel)mutation inKIT exon 11,
(2) presence of a mutation that involves exon 11 codon 557
and/or codon 558 (a deletion or indel mutation or a substitu-
tionmutation), (3)presenceofadeletionor indelmutation that
involves codon 557 and/or codon 558, and (4) a deletion of
codons 557 and/or 558 only (leading to p.Trp557_Lys558del).
Statistical Analysis
WeselectedRFS as the survival end point for this exploratory
study because RFS was also the primary objective in the
SSGXVIII/AIO trial5 andmore RFS events occurred compared
withOSevents, thusprovidingmorestatisticalpower (Figure1).
We defined RFS as the interval between the date of random-
ization and the date of first documentation of GIST recur-
rence or death, whichever occurred first, censoring patients
whowere alive without recurrence on the date of the last fol-
low-up visit. Overall survival was calculated from the date of
randomization to the date of death.
Survival between groups was compared using the Kaplan-
Meier life-table method and an unstratified log-rank test. Fre-
quency tables were analyzed using the χ2 test. Continuous
distributions between groups were compared with the Mann-
Whitney test. The P values are 2-sided and not adjusted for
multiple testing. P < .05 indicates a significant finding. The
data from the evaluable population were analyzed from
February 4, 2004, through December 31, 2013, using an
SPSS statistical software, version 22.0 (SPSS Inc).
Results
KIT and PDGFRAMutations
Of the 341 patients (median age at study entry, 62 years [in-
terquartile range (IQR), 52-68 years]) in the 1-year group and
60 years [IQR, 50-68 years]) in the 3-year group; 92 males
[52.6%] in the 1-year groupand83 [47.4%] in the3-year group),
274 (80.4%) had GISTs with a KIT mutation, 43 (12.6%) had
GISTs that harbored a PDGFRAmutation, and 24 (7.0%) had
GISTs thatwerewild type for thesegenes (Table). A total of 149
(54.4%) of the KIT mutations were exon 11 deletion or indel
mutations. A total of 111 (74.5%) involved codon 557, 558, or
both, and 30 (20.1%) were deletions of 557 and 558, leading
to p.Trp557_Lys558del. Of all 274 KITmutations of any kind,
121 (44.2%) involved codons 557 and/or 558, 22 (8.0%) were
exon 11 duplication or insertion mutations, 68 (24.8%) were
Figure 1. Profile of the Study
200 Randomized to receive adjuvant
imatinib for 1 y
181 Included in the efficacy population
200 Randomized to receive adjuvant
imatinib for 3 y
19 Excluded
1 Did not provide consent
5 Did not have GISTs
13 Had metastases excised
at study entry
7 Did not have mutation analysis
174 Were included in the study
80 Had GIST recurrence
31 Died
177 Included in the efficacy population
23 Excluded
2 Did not provide consent
10 Did not have GISTs
11 Had metastases excised
at study entry
10 Did not have mutation analysis
167 Were included in the study
62 Had GIST recurrence
18 Died
400 Patients randomized after surgery
GISTs indicate gastrointestinal
stromal tumors.
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exon 11 substitutionmutations, and26 (9.5%)were exon9du-
plicationmutations (all leading to p.Ala502_Tyr503dup). The
highestmedianmitotic countswere present inGISTs that had
deletionof codons557and558, leading top.Trp557_Lys558del
(17 mitoses per 50 HPFs), and the lowest counts were in tu-
mors with PDGFRA mutation (1 mitosis per 50 HPFs). GISTs
with a KIT exon 11 deletion or indel mutation harbored ame-
dian of 8 mitoses per 50 HPFs (eTable 1 in the Supplement).
Mutation Type and RFS
During the follow-up, 80 RFS events occurred in the 1-year
group and 62 in the 3-year group. Patients whose GISTs har-
bored aPDGFRAmutation, aKIT exon 11 duplication or inser-
tionmutation,or aKITexon11 substitutionmutationhadmore
favorable RFS than patients with aKIT exon 11 deletion or in-
delmutation, andpatientswith aKITexon9mutationhad the
worst outcome (Figure 2A). Patients with a KIT exon 11 dele-
tion or indel mutation treated with 3 years of adjuvant imat-
inib treatmenthadsubstantiallybetterRFScomparedwithpa-
tients treated with 1 year of imatinib treatment (5-year RFS,
71.0% vs 41.3%; P < .001), whereas no significant difference
in RFS was observed in the other subgroups studied (5-year
RFS, 82.6% at 3 years and 60.8% at 1 year in patientswithKIT
exon 11 substitutionmutation and42.9%at 3 years and25.0%
at 1 year in patients with KIT exon 9 mutation) (Figure 2B-D
and eFigure 1 in the Supplement).
KIT Exon 11 Deletions That Involve Codon 557 and/or 558
Wenext investigated inmoredetail the largest subgroupofmu-
tations:KIT exon 11 deletions.When the patientswhohad any
KIT exon 11 deletion or indel mutation (n = 149) were com-
paredwith the rest of the patients, patients with aKIT exon 11
deletion or indel mutation had unfavorable RFS (5-year RFS,
57.5% vs 68.4%; P = .03) (eFigure 2 in the Supplement). Simi-
larly, 30 patients who had deletion of the KIT exon 11 codons
557 and558had less favorableRFS than the rest of thepatients
(5-year RFS, 48.3%vs 65.2%;P = .001), whereas no significant
difference inRFSwasfoundbetweenpatientswhohadanytype
ofKITexon11mutation involvingcodon557or558 (5-yearRFS,
60.6%vs65.3%;P = .32)orbetweenpatientswhohadaKITexon
11 deletion or indelmutation that involved 557 and/or 558 and
the rest of the patients (5-year RFS, 57.7% vs 66.4%; P = .07).
TheprognosticsignificanceofthedifferenttypesofKITexon
11mutationsforRFSdependedonthedurationofadjuvant imat-
inibadministered.PresenceofaKITexon11deletionor indelmu-
tation, aKIT exon 11mutation that involved codons 557 and/or
558, anexon11deletionor indelmutation that involvedcodons
557 and/or 558, and adeletionmutationof codons 557 and558
were each significantly associatedwith unfavorable RFS com-
paredwiththerestof thepatients in thesubgroupofpatientsas-
signed to 1yearof imatinib treatment, butnosuchassociations
werepresentamongpatientswhowereassignedto3yearsofima-
tinib treatment (Figure3andeFigure3 in theSupplement). Be-
cause the assumption for proportionalitywasnot valid, the in-
teractionbetweenthedurationofadjuvantimatinibandthepres-
ence of KIT deletion mutation was not tested in a linear
multivariablemodel. Themain prognostic factorswere gener-
ally similarlydistributedbetween the 1-year and3-year arms in
thesubgroupsofpatientswithdifferent typesofKITexon11de-
letionmutations (eTables 2, 3, and 4 in the Supplement).
PatientswithKITexon11deletionor indelmutationhadbet-
ter OS than the rest of the patients in the entire cohort (5-year
OS, 93.5%vs 87.3%; P = .04), but no significant differencewas
found in the 1-year (5-year OS, 88.9% vs 85.7%; P = .27) and
3-year (5-year OS, 97.3% vs 89.1%; P = .06) subsets.
KIT Exon 11 DeletionMutations andMitotic Counts
To further examine theassociationsbetweenKITdeletionmu-
tationsandthedurationofadjuvant imatinibtreatment,wenext
investigatedhowthedurationof adjuvant imatinib influences
Table. Characteristics of the 341 Patients in the Scandinavian Sarcoma
Group VIII/Arbeitsgemeinschaft Internistische Onkologie Trial
WithMutation Analysis for KIT and PDGFRAAvailablea
Characteristic
1 y of Adjuvant
Imatinib Treatment
(n = 174)
3 y of Adjuvant
Imatinib Treatment
(n = 167)
Age at study entry, median (IQR), y 62 (52-68) 60 (50-68)
Sex
Male 92 (52.6) 83 (47.4)
Female 82 (49.4) 84 (50.6)
Tumor diameter, median (IQR), cm 9.5 (6-13) 10 (7-13)
Tumor location
Gastric 87 (47.5) 96 (52.5)
Nongastric 86 (55.1) 70 (44.9)
Not available 1 1
Tumor mitotic countb
<6 79 (50.0) 79 (50.0)
6-10 26 (50.0) 26 (50.0)
>10 66 (54.1) 56 (45.9)
Not available 3 6
Tumor rupture before or at surgery
No 144 (53.3) 126 (46.7)
Yes 30 (42.3) 41 (57.7)
KIT
Exon 9 12 (46.2) 14 (53.8)
Exon 11
Deletion 45 (44.1) 57 (55.9)
Insertion-deletion 26 (55.3) 21 (44.7)
Duplication or insertion 13 (59.1) 9 (40.9)
Substitution 38 (55.9) 30 (44.1)
PDGFRA
Exon 12 3 (60.0) 2 (40.0)
Exon 18 20 (52.6) 18 (47.4)
Other mutationc 3 (33.3) 6 (66.7)
Wild type for KIT and PDGFRA 14 (58.3) 10 (41.7)
Abbreviations: IQR, interquartile range; KIT, KIT proto-oncogene receptor
tyrosine kinase; PDGFRA, platelet-derived growth factor receptor α.
a Data are presented as number (percentage) of patients unless otherwise
indicated.
bCounts per 50 high-power fields of themicroscope at central review of the
tumor specimens.
c Includes 4 tumors with a KIT exon 13 mutation, 2 tumors with a KIT exon 11
duplication or insertionmutation plus a substitutionmutation, 1 with a KIT
exon 11 insertionmutation plus an insertion-deletionmutation, 1 with a KIT
exon 11 deletionmutation plus a KIT exon 11 insertionmutation, and 1 with an
unspecified KITmutation.
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the prognostic significance of the tumormitotic count in sub-
sets of patientswithdifferent typesofKITdeletionmutations.
In these analyses, we used themedianmitotic count of GISTs
withKITdeletionmutationinthecentralhistopathologicreview
as the cutoff value (8mitoses per 50HPFs). The tumormitotic
countwassignificantlyassociatedwithRFS inthesubsetsofpa-
tientswhohadKITdeletionor indelmutation(5-yearRFS,54.5%
vs 28.4%; P = .01) or who had anyKITmutation that involved
codons 557 and/or 558 (5-year RFS, 55.2% vs 30.8%; P = .05)
when thepatientshadbeenassigned to the 1-year groupof the
trial,butmitoticcountwasnotsignificantlyassociatedwithRFS
in these subgroupswhen thepatientshadbeenassigned to the
3-year arm (Figure 4 and eFigure 4 in the Supplement).
Discussion
Few data are available on how the duration of adjuvant imat-
inib treatment influences the risk of recurrence related to dif-
ferentGISTgenotypes.WefoundthatpatientswhoseGISThar-
borsKITexon11deletionmutationbenefitmost fromthe3-year
adjuvant treatment,whereaspatientswithothermutationshad
less or no benefit.KIT exon 11 deletionmutations,KIT exon 11
mutations that involved the codons 557 and/or 558, and de-
letions that led to p.Trp557_Lys558del were each signifi-
cantly associated with unfavorable RFS in the subset of pa-
tients randomized to 1 year of imatinib treatment but not
among those randomized to 3 years. When we examined the
prognostic significance of tumor mitotic count in the sub-
group of patients with KIT exon 11 deletion mutations, mi-
totic countwas significantly associatedwithunfavorableRFS
amongonlypatientsassignedtothe1-yeargroupbutnotamong
those assigned to the 3-year group.
Toourknowledge, theobservation that thedurationof ad-
juvant imatinib treatment influences the clinical significance
of important prognostic factors, such as tumor mitotic count
and tumor genotype, is novel. In the adjuvant setting, the du-
ration of imatinib administration may thus influence pro-
Figure 2. Associations of KIT Proto-oncogene Receptor Tyrosine Kinase (KIT) and Platelet-Derived Growth Factor Receptor α (PDGFRA)
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foundly themolecular biology of some GISTs. Thismight not
beasevident inadvancedGISTs, inwhich the ratesofGISTpro-
gression may not differ markedly after imatinib therapy dis-
continuation after variable durations of imatinib treatment.21
In thepreplannedsubgroupanalysesof theSSGXVIII/AIO trial,
patients who had GISTs with a high mitotic count (>10 mito-
ses per 50 HPFs) and those with KIT exon 11 deletion muta-
tion benefited most from the 3-year adjuvant treatment,
whereas patients whose GISTs had a lower count (<10 mito-
ses) did not benefit.18 These findings suggest that longer ad-
juvant imatinib treatmenteradicatesmoreefficientlyGISTcells
that harbor imatinib-sensitiveKITmutations and have a high
cell proliferation rate than the shorter treatment.
The finding that patientswithKIT exon 11 deletionmuta-
tion benefitmost from the longer adjuvant treatment is in ac-
cordance with prior observations.16,22 Patients with ad-
vanced GISTs with KIT exon 11 mutation respond frequently
to imatinib and have longer progression-free survival com-
paredwith patientswith exon 9KITmutation or thosewhose
GISTs lack KIT and PDGFRAmutations.16 In one study,22 pa-
tients with KIT exon 11 mutation that involved codons 557
and/or 558 responded to imatinib more frequently than pa-
tients with a KIT exon 11 mutation that did not involve these
codons. In theAmericanCollege of SurgeonsOncologyGroup
Z9001 trial that compared 1 year of adjuvant imatinib to 1 year
of placebo, patients with aKIT exon 11 deletionmutation had
higherRFSwhen randomized to imatinib,whereas no signifi-
cant RFS benefit was found among patients with KIT exon 11
insertion or substitution mutation, KIT exon 9 mutation,
PDGFRAmutation, or GISTs that were wild type for KIT and
PDGFRA.7
These current findings have several consequences. They
mayhelptoexplainwhyanOSbenefitemerged intheSSGXVIII/
AIOtrial in favorof the3-yeargroup,whereasnoOSbenefitwas
observed in the 2 randomized trials that evaluated shorter du-
rations of adjuvant imatinib and that also accrued lower-risk
patients.7,8 The current findings suggest that longer adjuvant
treatments tend to result in less steep slopes of the RFS curves
whenadjuvant imatinib isdiscontinued,whichmaybe thecase
(eFigure5 in theSupplement).Thepresent findings furthersug-
gest that patientswithGISTs treatedwith longdurationsof ad-
juvant imatinib may need to be followed up longer for tumor
recurrence because some of the recurrent tumorsmay surface
latedespite thepresenceofhigh-risk features at the timeof the
diagnosis. More important, studies that evaluate the prognos-
tic factors of localized GISTs now not only need to consider
whether adjuvant imatinib was administered but also need to
take into account the duration of adjuvant imatinib.
Figure 3. Associations of KIT Proto-oncogene Receptor Tyrosine Kinase (KIT) Exon 11 DeletionMutationsWith Recurrence-Free Survival
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Limitations
Alimitationof thisexplorativestudy is that themutational sub-
groupswerenotpredefined in the trial protocol. To reduce the
risk for a type I error, we focused on commonly used muta-
tional subgroups. Variable definitions for the aberrations that
affect KIT exon 11 codons 557 and/or 558 have been
used,12,14,15,22 and, therefore, we classified these mutations
using 3 categories. Because the size of somemutational sub-
groups was small, the statistical power to detect a treatment
effectmayhave remained insufficient.Mutation analysiswas
not available for 17 (4.7%) of the 358 patients in the SSGXVIII/
AIO trial efficacy population, but no bias in the frequency of
themost important prognostic factorswas foundbetweenpa-
tients with andwithoutmutation analysis available. Patients
withKIT exon9mutationmight havebenefited froman imat-
inibdosehigher than400mg/d,17 but thiswasunknownat the
time the trial was designed.
Conclusions
The duration of adjuvant imatinib influences the risk of GIST
recurrence associated with KIT deletion mutations. The ad-
verse prognostic influence of some frequentmutations, such
as deletion mutations that involve KIT exon 11 codons 557
and/or 558, was no longer detectable in patients treated with
adjuvant imatinib for 3 years. Tumor mutation analysis aids
in the selectionofpatients for adjuvant imatinib treatmentbe-
causepatientswithKITdeletionmutationsbenefitmore from
3 years of adjuvant imatinib than patients with other muta-
tions, andsomeGISTs,notably thosewithPDGFRAD842Vmu-
tation, are considered imatinib resistant.23 Two ongoing ran-
domized trials24,25 are currently comparing 5 vs 3 years and 6
vs 3 years of adjuvant imatinib treatment to evaluatewhether
still longer adjuvant treatmentswill provide further benefits.
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